Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10

Melanoma Research

Volumn 9, Issue 3, 1999, Pages 261-272

  Ekmekcioglu, S ^a   Okcu, M F ^a   Colome Grimmer, M I ^a   Owen Schaub, L ^a   Buzaid, A C ^b   Grimm, E A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

FasL; Human; IFN ; IL 10; Melanoma

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FAS ANTIGEN; INTERLEUKIN 10; MESSENGER RNA; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032822064     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199906000-00008     Document Type: Article

References (37)

1. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
2. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Goldstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 1995; 181: 781-786.
3. Glass A, Walsh CM, Lynch DH, Clark WR. Regulation of the Fas lytic pathway in cloned CTL. J Immunol 1996; 156: 3638-3644.
4. Anel A, Simon AK, Auphan N, Buferne M, Boyer C, Golstein P, Schmitt-Verhulst AM. Two signalling pathways can lead to Fas ligand expression in CD8+ cytotoxic T lymphocyte clones. Eur J Immunol 1995; 25: 3381-3387.
5. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997; 158: 5676-5684.
6. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1996; 57: 129-144.
7. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Klebanoff J, Ledbetter JA, Liles WC. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997; 185(8): 1511-1516.
8. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC. Human monocytic cells contain high levels of intracellular Fas ligand. Rapid release following cellular activation. J Immunol 1997; 159: 1594-1598.
9. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
10. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornard T, Fontana A, Lienard D, Cerottini JC, Tschopp J Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363- 1366.
11. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
12. Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56: 755-760.
13. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunity 1995; 41(3): 151-156.
14. Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T, Diamantstein T. Expression of interleukin 10 in human melanoma. Br J Cancer 1994;70:1182-1185.
15. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res 1996; 2: 1383-1390.
16. Dummer W, Bastian B, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66: 607-610.
17. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette III DC, Birchenall-Roberts MC. Vitamin E succinate induces fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 1997; 57: 881-890.
18. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185-192.
19. Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R, Dorken B. Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Eur J Immunol 1997; 27: 1029-1043.
20. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373: 438-441.
21. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
22. Parijs L, Abbas AK. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996; 8: 355-361.
23. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449-1456.
24. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stemmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/ Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
25. Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994; 84: 1201-1208.
26. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
27. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr opin Oncol 1995; 7: 175-184.
28. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-β-dependent but not the transforming growth factor-β-independent pathway of tumor cell-mediated immuno-suppression. J Immunol 1992; 148: 277-284.
29. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172(5): 902-908.
30. Carrel S, Dore JF, Ruiter DJ, Prade M, Lejeune FJ, Kleeberg UR, Rumke P, Brocker EB. The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer 1991; 48: 836-847.
31. Holzmann B, Lehmann JM, Ziegler-Heitbrock HWL, Funke I, Riethmuller G, Johnson JP. Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. Int J Cancer 1988; 41: 542-547.
32. Carrel S, Zografos L, Schreyer M, Rimoldi D. Expression of CALLA/CD10 on human melanoma cells. Melanoma Res 1993; 3: 319-323.
33. Brocker EB, Suter L, Bruggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985; 36: 29-35.
34. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Tagahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-6425.
35. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58: 1741-1749.
36. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
37. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. Human melanoma cells do not express Fas (Apo/ CD95) ligand. Cancer Res 1999; 59: 59-62.